Clifford A. Hudis, MD: A Message From ASCO’s CEO
2024 ASCO Annual Meeting
Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Welcome, everybody, to the 60th Annual ASCO Meeting. This meeting is an especially meaningful and exciting one for me because this comes on the heels of decades of really powerful advances across all of oncology, including, of course, targeted therapy, small molecules, immunotherapy, and engineered cells, among many other advances that I'd say in the last five to 10 years have truly transformed oncology. But what makes this year's meetings especially exciting, is that we have coupled this with a call for humanism in medicine and a reminder of the privilege of caring for patients and families through this most difficult time. Our president, Dr. Lynn Schuchter, who's been on the leading edge of the most exciting advances in cancer, especially those in melanoma, at the same time is one of the most compassionate, holistic kinds of physicians anyone could hope to see, and she brings that with passion to this meeting. So we're very, very excited by the inclusion of so many new resources and learnings for our community to help them help their patients around the world more effectively than ever before.
The ASCO Post Staff
Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).
The ASCO Post Staff
Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases. Tumor treating fields therapy prolongs time to intracranial disease progression and may postpone whole-brain radiation therapy without declines in quality of life and cognition (Abstract 2008).
The ASCO Post Staff
Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO), and Karen E. Knudsen, MBA, CEO of the American Cancer Society, discuss a newly launched collaboration between the organizations to make it simpler for patients to find authoritative cancer information online. The effort creates one of the largest and most comprehensive online resources for credible cancer information, available for free to the public on cancer.org.
The ASCO Post Staff
Efrat Dotan, MD, of Fox Chase Cancer Center, discusses results from the phase II EA2186 trial, the first prospective study aiming to define the optimal treatment approach for vulnerable older adults with newly diagnosed metastatic pancreatic cancer (Abstract 4003).
The ASCO Post Staff
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus venetoclax continues to provide clinically meaningful progression-free disease in those with high-risk genomic features as well as in the overall population (Abstract 7009).
